Literature DB >> 32239695

Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.

Rex K H Au-Yeung1,2, Laura Arias Padilla3, Martin Zimmermann4, Ilske Oschlies1, Reiner Siebert5, Wilhelm Woessmann6, Birgit Burkhardt3, Wolfram Klapper1.   

Abstract

Large B-cell lymphoma with IRF4 rearrangement, and Burkitt-like lymphoma with 11q aberration are two provisional lymphoma entities in the 2017 revision of the WHO classification of lymphoid neoplasms. Despite being more frequent in young patients, knowledge regarding their true incidence and clinical features in unselected cohorts of paediatric and adolescent patients is limited. We screened for both entities among paediatric patients (<18 years of age) in the German NHL-BFM (Non-Hodgkin lymphoma Berlin-Frankfurt-Münster) group. Among follicular lymphomas and diffuse large B-cell lymphomas (DLBCL), 7/34 cases (21%) showed an IRF4 break-apart pattern by fluorescence in situ hybridisation (FISH) and are associated with stages I and II disease (P = 0·043). Among lymphomas morphologically resembling Burkitt lymphoma, DLBCL and high-grade B-cell lymphoma, unclassifiable, 13/102 cases (13%) lacked a MYC break-apart pattern but were positive for 11q proximal gain and telomeric loss by FISH. MYC-negative Burkitt-like lymphomas with the typical 11q gain-loss pattern by FISH were older (P = 0·004), showed less male predominance (P = 0·003), lower stage (P = 0·040), lower serum LDH level (P = 0·01) and less abdominal involvement (P = 0·008) compared to high grade B-cell lymphomas without 11q gain-loss pattern. Both entities showed excellent outcome with overall survival of 100% when managed according to NHL-BFM strategies and may provide candidates for future therapy de-escalation in clinical trials.
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  B cells; chromosome 11q; non-Hodgkin lymphoma; paediatric haematology; paediatric oncology

Year:  2020        PMID: 32239695     DOI: 10.1111/bjh.16578

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hematolymphoid Proliferations and Neoplasia.

Authors:  Judith A Ferry
Journal:  Head Neck Pathol       Date:  2022-03-21

2.  The EHA Research Roadmap: Malignant Lymphoid Diseases.

Authors:  Martin Dreyling; Marc André; Nicola Gökbuget; Hervé Tilly; Mats Jerkeman; John Gribben; Andrés Ferreri; Pierre Morel; Stephan Stilgenbauer; Christopher Fox; José Maria Ribera; Sonja Zweegman; Igor Aurer; Csaba Bödör; Birgit Burkhardt; Christian Buske; Maria Dollores Caballero; Elias Campo; Bjoern Chapuy; Andrew Davies; Laurence de Leval; Jeanette Doorduijn; Massimo Federico; Philippe Gaulard; Francesca Gay; Paolo Ghia; Kirsten Grønbæk; Hartmut Goldschmidt; Marie-Jose Kersten; Barbara Kiesewetter; Judith Landman-Parker; Steven Le Gouill; Georg Lenz; Sirpa Leppä; Armando Lopez-Guillermo; Elizabeth Macintyre; Maria Victoria Mateos Mantega; Philippe Moreau; Carol Moreno; Bertrand Nadel; Jessica Okosun; Roger Owen; Sarka Pospisilova; Christiane Pott; Tadeusz Robak; Michelle Spina; Kostas Stamatopoulos; Jan Stary; Karin Tarte; Allessandra Tedeschi; Catherine Thieblemont; Ralf Ulrich Trappe; Lorenz H Trümper; Gilles Salles
Journal:  Hemasphere       Date:  2022-05-19

Review 3.  Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature.

Authors:  Renata Woroniecka; Grzegorz Rymkiewicz; Lukasz M Szafron; Katarzyna Blachnio; Laura A Szafron; Zbigniew Bystydzienski; Barbara Pienkowska-Grela; Klaudia Borkowska; Jolanta Rygier; Aleksandra Kotyl; Natalia Malawska; Katarzyna Wojtkowska; Joanna Parada; Anita Borysiuk; Victor Murcia Pienkowski; Malgorzata Rydzanicz; Beata Grygalewicz
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

4.  Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.

Authors:  Leonie Frauenfeld; Natalia Castrejon-de-Anta; Joan Enric Ramis-Zaldivar; Sebastian Streich; Julia Salmerón-Villalobos; Franziska Otto; Annika Katharina Mayer; Julia Steinhilber; Magda Pinyol; Barbara Mankel; Colleen Ramsower; Irina Bonzheim; Falko Fend; Lisa M Rimsza; Itziar Salaverria; Elias Campo; Olga Balagué; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2022-04-12

5.  Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation.

Authors:  Karoline Koch; Julia Richter; Christoph Hanel; Andreas Huttmann; Ulrich Duhrsen; Wolfram Klapper
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

6.  Burkitt-like lymphoma with 11q aberration confirmed by needle biopsy of the liver: A case report.

Authors:  Han-Jin Yang; Zhao-Ming Wang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

7.  Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.

Authors:  Maher Albitar; Hong Zhang; Andre Goy; Zijun Y Xu-Monette; Govind Bhagat; Carlo Visco; Alexandar Tzankov; Xiaosheng Fang; Feng Zhu; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Fredrick B Hagemeister; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Yong Li; Bing Xu; Ken H Young
Journal:  Blood Cancer J       Date:  2022-02-01       Impact factor: 9.812

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.